114 lines
No EOL
16 KiB
XML
114 lines
No EOL
16 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-table" /><meta name="ncbi_acc" content="NBK578045" /><meta name="ncbi_domain" content="niceng136er3" /><meta name="ncbi_report" content="objectonly" /><meta name="ncbi_type" content="table" /><meta name="ncbi_objectid" content="ch3.tab3" /><meta name="ncbi_pcid" content="/NBK578045/table/ch3.tab3/?report=objectonly" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Table 3, Excluded reviews - Evidence review for initiating treatment - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="NOINDEX,NOFOLLOW,NOARCHIVE,NOIMAGEINDEX" /><meta name="author" content="National Guideline Centre (UK)" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Table 3, Excluded reviews" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)" /><meta name="DC.Contributor" content="National Guideline Centre (UK)" /><meta name="DC.Date" content="2019/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK578045/table/ch3.tab3/" /><meta name="bk-non-canon-loc" content="/books/n/niceng136er3/toc/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK578045/table/ch3.tab3/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8E09AD7D7387D100000000008D006C.m_5" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-table">
|
|
<div class="grid no_max_width">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
|
|
<div class="header">
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<div class="container content">
|
|
<div class="object">
|
|
|
|
<div class="main-content lit-style"><div class="body-content whole_rhythm"><div id="ch3.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Excluded reviews</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578045/table/ch3.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch3.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_ch3.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Systematic review</th><th id="hd_h_ch3.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exclusion reasons</th></tr></thead><tbody><tr><td headers="hd_h_ch3.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blood Pressure Lowering Trialists Collaboration IPD 2014<a class="bk_pop" href="/books/NBK578045/#ch3.ref163" data-bk-pop-rid="/books/NBK578045/def-item/ch3.ref163/" data-bk-pop-others=""><sup>163</sup></a></td><td headers="hd_h_ch3.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch3.l3"><li id="ch3.lt14" class="half_rhythm"><div>The study used a customised risk calculator to stratify participants into risk groups. It was unclear how risk was calculated and whether the groups were similar to validated risk tools such as Framingham, QRISK2 or 3. The risk calculator also used previous cardiovascular events, which is not considered a useful measure and is not included in any validated risk tools.</div></li><li id="ch3.lt15" class="half_rhythm"><div>The cardiovascular risk groups compared within each category also differed within each outcome, which made results difficult to interpret.</div></li><li id="ch3.lt16" class="half_rhythm"><div>The population didn’t match this review protocol’s requirements: unclear if participants were already treated or on other treatment (55.9% had previous treatment) and unclear if baseline cardiovascular risk was measured while participants were untreated. 39.1% of the population had diabetes with no detail of whether this was type 1 or type 2 diabetes.</div></li><li id="ch3.lt17" class="half_rhythm"><div>Pooled trial data of ‘less intensive arms’ with placebo, which was an exclusion criterion on the protocol for this review.</div></li><li id="ch3.lt18" class="half_rhythm"><div>No minimum trial duration inclusion criterion, whereas this review had a requirement of trials with a minimum duration of 12 months.</div></li><li id="ch3.lt19" class="half_rhythm"><div>The trialists used meta-regression with the observed 5-year risks to extend all results to 5 years; the average follow up time was not stated.</div></li></ul></td></tr><tr><td headers="hd_h_ch3.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blood Pressure Lowering Trialists Collaboration IPD 2011<a class="bk_pop" href="/books/NBK578045/#ch3.ref50" data-bk-pop-rid="/books/NBK578045/def-item/ch3.ref50/" data-bk-pop-others=""><sup>50</sup></a></td><td headers="hd_h_ch3.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch3.l4"><li id="ch3.lt20" class="half_rhythm"><div>For the blood pressure categories outlined in the protocol for this review, the only available outcome was major cardiovascular events. This composite outcome was included in the review protocol but was only to be included if individual cardiovascular event outcomes were not available. This is because these outcomes were considered to be more informative.</div></li><li id="ch3.lt21" class="half_rhythm"><div>Individual morbidity and mortality outcomes were given at systolic blood pressure thresholds of above 140 mmHg and below 140 mmHg. Above 140 mmHg was not a threshold listed in the protocol and would not have informed recommendations as this encompasses stage 1 and stage 2 hypertension. The below 140 mmHg comparison was considered for inclusion but 58.9% had other cardiovascular disease and were taking medication for secondary prevention.</div></li><li id="ch3.lt22" class="half_rhythm"><div>Baseline characteristics were not stated, and the IPD included participants that were already treated; it was unclear if baseline blood pressure had been measured while participants were untreated.</div></li></ul></td></tr><tr><td headers="hd_h_ch3.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Asayama 2009 IPD<a class="bk_pop" href="/books/NBK578045/#ch3.ref17" data-bk-pop-rid="/books/NBK578045/def-item/ch3.ref17/" data-bk-pop-others=""><sup>17</sup></a></td><td headers="hd_h_ch3.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch3.l5"><li id="ch3.lt23" class="half_rhythm"><div>Study carried out in Japan and considered not to be applicable to the UK population due to the known differences in antihypertensive treatment and prevalence of cardiovascular events, that is, different antihypertensive drugs administered and lower dosages of treatment given than in the UK. The prevalence of stroke and heart failure are higher in Japan, which were the only included outcomes in the IPD. In addition, the incidence of myocardial infarction tends to be lower in Japanese people with hypertension, which is an outcome of interest for this guideline.</div></li><li id="ch3.lt24" class="half_rhythm"><div>The comparisons included were not in line with this review protocol. Rather than comparing treatment versus no treatment at each blood pressure threshold, the IPD compared treatment at each threshold versus no treatment in the ‘optimal’ below 120 mmHg systolic blood pressure category. This would have substantially influenced the results.</div></li><li id="ch3.lt25" class="half_rhythm"><div>Unclear from the IPD whether baseline blood pressure was measured before treatment was initiated.</div></li></ul></td></tr><tr><td headers="hd_h_ch3.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brunström 2016<a class="bk_pop" href="/books/NBK578045/#ch3.ref40" data-bk-pop-rid="/books/NBK578045/def-item/ch3.ref40/" data-bk-pop-others=""><sup>40</sup></a></td><td headers="hd_h_ch3.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch3.l6"><li id="ch3.lt26" class="half_rhythm"><div>There is an overlap in included studies included in this review with those included in Sundstrom 2015.<a class="bk_pop" href="/books/NBK578045/#ch3.ref162" data-bk-pop-rid="/books/NBK578045/def-item/ch3.ref162/" data-bk-pop-others=""><sup>162</sup></a> The IPD (Sundstrom) was therefore preferentially included.</div></li></ul></td></tr><tr><td headers="hd_h_ch3.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Emdin 2005<a class="bk_pop" href="/books/NBK578045/#ch3.ref55" data-bk-pop-rid="/books/NBK578045/def-item/ch3.ref55/" data-bk-pop-others=""><sup>55</sup></a></td><td headers="hd_h_ch3.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch3.l7"><li id="ch3.lt27" class="half_rhythm"><div>There is an overlap in included studies included in this review with those included in Sundstrom 2015.<a class="bk_pop" href="/books/NBK578045/#ch3.ref162" data-bk-pop-rid="/books/NBK578045/def-item/ch3.ref162/" data-bk-pop-others=""><sup>162</sup></a> The IPD (Sundstrom) was therefore preferentially included.</div></li><li id="ch3.lt28" class="half_rhythm"><div>Stratified by above 140 mmHg and below 140 mmHg; above 140 mmHg was not a threshold listed in the protocol and would not have informed recommendations as this encompasses stage 1 and stage 2 hypertension. 65% of the population in the below 140 mmHg threshold had other cardiovascular disease and were taking antihypertensive medication for secondary prevention</div></li></ul></td></tr><tr><td headers="hd_h_ch3.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ettehad 2016<a class="bk_pop" href="/books/NBK578045/#ch3.ref57" data-bk-pop-rid="/books/NBK578045/def-item/ch3.ref57/" data-bk-pop-others=""><sup>57</sup></a></td><td headers="hd_h_ch3.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch3.l8"><li id="ch3.lt29" class="half_rhythm"><div>Majority of participants had coronary heart disease and 15–40% had heart failure, which were not included in this review.</div></li></ul></td></tr></tbody></table></div></div></div></div>
|
|
<div class="post-content"><div><p>From: <a href="/books/NBK578045/" target="mainwindow">Evidence review for initiating treatment</a></p><div class="iconblock clearfix ten_col"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/niceng136er3/" target="mainwindow"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng136er3-lrg.png" alt="Cover of Evidence review for initiating treatment" height="100px" width="80px" /></a><div class="icnblk_cntnt"><div><div>Evidence review for initiating treatment: Hypertension in adults: diagnosis and management: Evidence review C.</div><div class="series-statement">NICE Guideline, No. 136.</div><div>National Guideline Centre (UK).</div><div>London: <a href="https://www.nice.org.uk" target="mainwindow" ref="pagearea=content-footer&targetsite=external&targetcat=link&targettype=publisher">National Institute for Health and Care Excellence (NICE)</a>; 2019 Aug.</div></div></div></div><div class="half_rhythm"><a href="/books/about/copyright/" target="mainwindow">Copyright</a> © NICE 2019.</div><p>NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p></div></div>
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-table&ncbi_acc=NBK578045&ncbi_domain=niceng136er3&ncbi_report=objectonly&ncbi_type=table&ncbi_objectid=ch3.tab3&ncbi_pcid=/NBK578045/table/ch3.tab3/?report=objectonly&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |